NEW YORK (360Dx) — Sienna Cancer Diagnostics said today that it has signed a South Korean distribution agreement for its bladder cancer diagnostic with Mirax.
Sienna's in vitro diagnostic is designed to detect the hTERT component of telomerase, a biomarker that aids in the diagnosis of bladder cancer alongside standard urine cytology testing. Under the terms of the deal, Gyeonggi-do-based Mirax will be the exclusive distributor of the test in the Republic of Korea and assist Sienna in securing its regulatory approval.
Additional terms were not disclosed.
"This partnership is another step in our geographical expansion program and creates further opportunity in the fast-growing Asian IVD market," Sienna CEO Matthew Hoskin said in a statement.
In August, Melbourne, Australia-based Sienna signed on Shaanxi GaoYuan In Vitro Diagnostic Reagents as the exclusive distributor of the test in mainland China. The firm has also signed distribution deals for the test covering the US, Denmark, Sweden, and Switzerland.